Please provide your email address to receive an email when new articles are posted on . One study showed semaglutide and tirzepatide raised the risk for nonarteritic anterior ischemic optic. Another ...

Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need for ...

GLP-1 RAs are linked to an increased risk of NAION in type 2 diabetes patients, with semaglutide and liraglutide showing significant associations. The study involved over 3.8 million Medicare patients ...

A Medicare cohort study of nearly 4 million older patients with type 2 diabetes found 2 in 1000 developed nonarteritic anterior ischemic optic neuropathy (NAION) over a period of more than 3 years.

About The Study: This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic ...

Research from the iMIND lab at Duke University. As a medical student, I have had the opportunity to join the iMIND lab at Duke University and contribute to the growing and captivating ...

Background: Giant cell arteritis (GCA) is a granulomatous vasculitis in older individuals that primarily affects medium-to-large vessels. Owing to the involvement of the ophthalmic arteries, GCA can ...

Researchers reviewed the risk factors of developing nonarteritic anterior ischemic optic neuropathy in patients using semaglutide medications. Patients taking semaglutide should be monitored closely ...

Ozempic blindness isn’t a real diagnosis. It’s a nickname used to describe sudden vision loss that may be linked to the weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, ...